高级搜索
立即登录 | 免费注册
当前位置 >   首页 > 医药资讯 >  药品动态  > 药品资讯内容

ED膳食补充剂被召回

Erectile dysfunction 'dietary supplement' recalled after FDA finds it contains undeclared tadalafil

2010-08-11 【发表评论】
中文 | ENGLISH | 打印| 推荐给好友


ST LOUIS (MD Consult) - On August 6, 2010, the US Food and Drug Administration (FDA) announced that EZVille, Ltd has recalled Revivexxx Extra Strength, a product marketed as a dietary supplement for sexual enhancement in men. The decision to conduct the recall was made after the FDA informed the company that a product analysis revealed the presence of undeclared tadalafil. Tadalafil is an FDA-approved drug for the treatment of male erectile dysfunction, making Revivexxx Extra Strength an unapproved drug.

The FDA believes that the use of this product could pose a threat to consumers because tadalafil may interact with nitrates found in some prescription drugs (eg nitroglycerin) and may lower blood pressure to dangerous levels. However, no illnesses or injuries have been reported to the company to date in connection with this product.

Revivexxx Extra Strength is packaged in a single-dose blister pack containing 1 oral tablet and bears Universal Product Code 8 35470 00207 9. All lots of this product with expiration dates including and prior to August 2013 currently available on the market are being recalled. The company has discontinued distribution of the affected product.

Consumers are being advised to contact their physician if they have experienced any problems that may be related to use of this product. Health care professionals and patients are encouraged to report adverse events related to product use to the FDA's MedWatch Program.

圣路易斯(MD Consult)——美国食品药品管理局(FDA)于2010年8月6日宣布,EZVille公司决定召回其产品Revivexxx Extra Strength,该产品作为一种提高男性性欲的膳食补充剂在市场上销售。此次召回决定是在FDA正式通知该公司其产品含有未申明成分他达拉非(tadalafil)后作出的。他达拉非是FDA批准用于治疗男性勃起功能障碍(ED)的药物,因而Revivexxx Extra Strength被视为未经批准的药物。
 
FDA认为,服用该产品可能会给消费者构成威胁,因为他达拉非可与一些处方药物(如硝酸甘油)中的硝酸盐相互作用,从而导致血压降低至危险水平。然而截至目前为止,该公司尚未收到有关该产品所导致疾病或伤害的报告。
 
Revivexxx Extra Strength的包装形式为含有1片的单剂量泡罩包装,并印有通用产品代码8 35470 00207 9。目前市售的使用截止日期在2013年8月及其之前的所有批次产品均在召回之列。该公司已经停止相关产品配送。
 
建议消费者一旦出现任何可能与该产品使用有关的问题时,应与医生联系。鼓励医护人员和患者向FDA MedWatch Program系统报告与该产品使用有关的不良事件。

Subjects:
general_primary
学科代码:
内科学

请登录后发表评论, 点击此处登录。

疾病资源中心  疾病资源中心
 病例分析

 王燕燕 王曙

上海交通大学附属瑞金医院内分泌科

患者,女,69岁。2009年1月无明显诱因下出现乏力,当时程度较轻,未予以重视。2009年3月患者乏力症状加重,尿色逐渐加深,大便习惯改变,颜色变淡。4月18日入我院感染科治疗,诉轻度头晕、心慌,体重减轻10kg。无肝区疼痛,无发热,无腹痛、腹泻、腹胀、里急后重,无恶性、呕吐等。入院半月前于外院就诊,查肝功能:ALT 601IU/L,AST 785IU/L,TBIL 97.7umol/L,白蛋白 41g/L,甲状腺功能:游离T3 30.6pmol/L,游离T4 51.9pmol/L,心电图示快速房颤。
 

医学数据库  医学数据库



友情链接:中文版柳叶刀 | MD CONSULT | Journals CONSULT | Procedures CONSULT | eClips CONSULT | Imaging CONSULT | 论文吧 | 世界医学书库 医心网 | 前沿医学资讯网

公司简介 | 用户协议 | 条件与条款 | 隐私权政策 | 网站地图 | 联系我们

 互联网药品信息服务资格证书 | 卫生局审核意见通知书 | 药监局行政许可决定书 
电信与信息服务业务经营许可证 | 京ICP证070259号 | 京ICP备09068478号

Copyright © 2009 Elsevier.  All Rights Reserved.  爱思唯尔版权所有